Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Tribune News Service

Tentative $161.5 million settlement reached in opioid trial

Attorneys for the state of West Virginia and two remaining pharmaceutical manufacturers have reached a tentative $161.5 million settlement

The Independent UK

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

StockNews.com

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

Benzinga

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young

Benzinga

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Axios

Read news from The Economist, FT, and more,
with one subscription

New Cancer Immunotherapy Fails in First Roche Trial

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

Asharq Al-Awsat

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb's (BMY) outstanding clinical and operational performance, as well as the current momentum across its product portfolio, have enabled the biopharmaceutical concern to post stable revenue growth in its most recent quarterly earnings release. In addition, the stock is currently trading at a discounted valuation despite generating substantial…

StockNews.com

CSL profit falls due to pandemic curbs

Blood products giant CSL says that its ability to collect plasma has been improving as social mobility increases.

AAP

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Los Angeles Times

Drug industry dollars flow into congress

KHN's Pharma Cash to Congress database reveals how the drug industry attempts to influence politics

Salon

Pharma campaign cash delivered to key lawmakers with surgical precision

The Biden administration and Congress are embroiled in high-stakes haggling over what urgent priorities will make it into the ever-shrinking social spending bill. But for the pharmaceutical industry there is one agenda: Heading off Medicare drug price negotiation, which it considers an existential threat to its business model.

Tribune News Service

Portugal scraps quarantine for Brits who had Indian-made Astra Zeneca jab

Portugal is expected to lift quarantine requirements for Britons who have had an Indian-made AstraZeneca vaccine.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

ABC News

WA Premier says under-40s should not get Astra Zeneca based on expert health advice

WA Premier Mark McGowan joins Queensland Premier Annastacia Palaszczuk in saying people under 40 should not get the AstraZeneca COVID vaccination, based on health advice.

Belfast Live

Astra Zeneca and Pfizer Covid-19 vaccines are effective and saving lives says NI Chief Medical Officer

Dr McBride moves to allay any doubts over Astra Zeneca claims and says there are no confirmed cases of South Africa variant of the virus in Northern Ireland

Wales Online

Oxford Astra Zeneca Covid-19 vaccine approved for use in the UK

It paves the way for a more rapid rollout of the vaccine

Reuters

South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation

South Korea's Celltrion Inc 068270.KS said on Monday it has received emergency use authorisation (EUA) from the U.S. Food Drug Administration (FDA) for its rapid COVID-19 testing kit Sampinute, which boosted shares of the company and its affiliates.

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Astra Zeneca shares surge on hopes of positive covid vaccine from project with Oxford University

Shares in drugs giant AstraZeneca surged 4% today on hopes of a breakthrough in its attempts to find a vaccine for covid-19.

USAFacts

The opioid crisis in data

In 2022 opioid overdose deaths reached a new peak of 81,806 , or just over 224 people each day.

1 … 137 138 139 140

People

Joe Biden

67,537 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.